Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Dar Al Dawa Development and Investment's average EBITDA Per Share Growth Rate was -5.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 40.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Dar Al Dawa Development and Investment was 40.80% per year. The lowest was -23.10% per year. And the median was 3.60% per year.
Dar Al Dawa Development and Investment (AMM:DADI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Dar Al Dawa Development and Investment 3-Year EBITDA Growth Rate Related Terms
AMM:DADI vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dar Al Dawa Development and Investment 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Dar Al Dawa Development and Investment's 3-Year EBITDA Growth Rate falls into.
Dar Al Dawa Development and Investment 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 40.80% mean?
Dar Al Dawa Development and Investment (AMM:DADI) has a 3-Year EBITDA Growth Rate of 40.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Dar Al Dawa Development and Investment and its competitors. This is 1033% above median its historical median of 3.60. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #115 out of 809 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Dar Al Dawa Development and Investment's 3-Year EBITDA Growth Rate too high?
Dar Al Dawa Development and Investment's current 3-Year EBITDA Growth Rate of 40.80% is 1033% above median its 10-year median of 3.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Dar Al Dawa Development and Investment's value of 40.80% is 358.4% above this industry median. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #115 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #115 out of 809 companies for 3-Year EBITDA Growth Rate. This places Dar Al Dawa Development and Investment in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Dar Al Dawa Development and Investment's value of 40.80% is 358.4% above this benchmark. While the company's 10-year median is 3.60 vs. the industry median of 8.90, Dar Al Dawa Development and Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dar Al Dawa Development and Investment's current 3-Year EBITDA Growth Rate of 40.80% is 358.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current 3-Year EBITDA Growth Rate is 40.80%, which is 1033% above median its own 10-year median of 3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Modestly Overvalued. The stock's GF Value™ is JOD1.03, compared to a current price of JOD1.22 — trading 18.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 40.80%, which is 1033% above median its 10-year median of 3.60 and 358.4% above the Drug Manufacturers industry median of 8.90. Dar Al Dawa Development and Investment's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current 3-Year EBITDA Growth Rate is 40.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued.
The current stock price of JOD1.22 is trading 18.4% above its estimated GF Value™ of JOD1.03.
GuruFocus considers Dar Al Dawa Development and Investment to be Modestly Overvalued.
Key valuation signals for AMM:DADI:
3-Year EBITDA Growth Rate: 40.80% (1033% above median its 10-year median of 3.60)
GF Value™: JOD1.03 vs. price of JOD1.22 (18.4% above fair value)
Industry Position: 358.4% above the Drug Manufacturers median (#115 of 809)
No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
78GF Score
Get the complete analysis for AMM:DADI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMM:DADI has been successfully added to your 
